News
News
Academy
Multimedia
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in Medicine
Conferences
Conference CoverageConference Listing
More
Publications
Pharmaceutical Executive
Partner Perspectives
Resources
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers

Subscribe

  • News
  • Academy
  • Multimedia
  • Conferences
  • Publications
  • Partner Perspectives
  • Resources
  • Subscribe
  • Corporate Communications
    • Press Releases
    • Executive Roundtable
    • Executive Profiles
    • Leadership
  • Direct-to-Consumer
    • Patient Education
    • Healthcare Access
    • Telehealth
  • Emerging Biopharma
    • Partnerships
    • Funding
  • IR Licensing and Partnerships
    • Finance
    • Industry Trends
  • Market Access
    • Patient Access
    • Pricing
    • Strategy
  • Medical Affairs
    • Patient Advocacy
    • Clinical Data
    • Pharmacovigilance
  • Operations
    • Sustainability
    • Technology
    • R&D/Clinical Trials
    • Supply Chain
  • Patient Engagement
    • DE&I
  • Regulatory
    • FDA
    • Legal
    • Global
  • Sales & Marketing
    • Sales Effectiveness
    • Campaigns
    • DTC Marketing
    • Medical Education
Spotlight -
Latest Executive Roundtables|
Asembia 2025 |
Sales Effectiveness
Advertisement

Claire Marrazzo Greenwood

Advertisement

Articles by Claire Marrazzo Greenwood

Matt Cabrey.jpg

The Roots and Rise of Cell and Gene Therapy

ByClaire Marrazzo Greenwood,Matt Cabrey
February 8th 2020

Continued investment will mean new cures in a new decade.

Advertisement

Latest Updated Articles

  • Matt Cabrey.jpg
    The Roots and Rise of Cell and Gene Therapy

    Published: February 8th 2020 | Updated:



Advertisement
Advertisement

Trending on PharmExec

1

Lilly’s Orforglipron, Retatrutide Named as Defining GLP-1 Drugs of the Next Decade

2

Eli Lilly Enters $1.2 Billion Definitive Agreement to Acquire Ventyx Biosciences

3

FDA Limits Regulations on Non-Medical Grade Wearable Fitness Devices

4

FDA Sends Decision Letter to Vanda Pharmaceuticals for NDA of Hetlioz

5

The Situation We Faced: Aaron Cowley, CSO, Recipharm Advanced Bio, Discusses Vision to Cut Biomanufacturing Timelines, Transform Continuous Manufacturing

  • About
  • Advertise
  • Contact Us
  • Editorial Board
  • Editorial Submission Guidelines
  • Do Not Sell My Personal Information
  • Privacy Policy
  • Terms and Conditions
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us